MEDVi Tirzepatide Review

MEDVi price at every dose tier

This is the table that decides your year. The advertised figure applies to the starter dose you occupy for roughly four weeks; the row to budget from is 10 mg.

Where MEDVi sits in the market

On first-year cost it ranks 14 of 16. The cheapest priced route, NexLife, comes in about $2,208 lower over the same year. Whether that gap is worth paying depends on what this programme provides that the cheaper one does not, which is a question about disclosure and service rather than about the molecule.

What MEDVi discloses before you pay

Pharmacy: not named. Visit model: async. Laboratory requirement: not required. Coaching: none published. Cancellation: 12-month plan for lowest rate.

Naming the dispensing pharmacy is the single most useful disclosure a programme can make, because it is the one fact that lets you check a state board register yourself before injecting anything weekly. Fewer than a fifth of the programmes we track publish it.

Who should not choose MEDVi

Anyone who expects to hold a low maintenance dose permanently: flat pricing is worst value at the bottom of the ladder. Anyone who needs an FDA-approved product, since this is a compounded preparation that FDA does not review for safety, effectiveness or quality before marketing. And anyone who cannot get a straight answer to the pharmacy question.

How the price behaves as your dose climbs

MEDVi charges $399 at 2.5 mg and $399 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you pay in month ten. That predictability is worth more than most entry discounts, and it is the single clearest thing this programme does well.

The corollary is that flat pricing is worst value at the bottom of the ladder. In month one you are paying a maintenance rate for an initiation dose. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled competitor may well beat this one.

What a longer horizon costs here

Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.

Commitment, refunds and what is at risk

The published prepaid rate is $249 a month on the multi-month plan, against $399 month to month — a saving of $150 a month. Compounded medication is generally not refundable once it ships, so treat the commitment as final. The sequencing that protects you is monthly billing until you have tolerated a maintenance dose for a cycle, prepaid after.

Cancellation: 12-month plan for lowest rate. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.

What this programme does not publish

MEDVi publishes everything our disclosure criteria measure, which is unusual. That is a statement about transparency, not about clinical quality or shipping reliability.

Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.

Seven questions before you enrol

1. What is the total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state?
4. What is the vial concentration and the beyond-use date?
5. Does the quoted rate hold at renewal, or revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel, and what is refundable before shipment?

None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.

Using it well if you do enrol

Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.

What MEDVi costs at each maintenance dose, over three years

Nobody knows their maintenance dose at intake, so a single annual figure is a guess about a decision a prescriber has not made. This is every plausible outcome for MEDVi, priced.

The spread between the cheapest and dearest outcome here is $0 a year. That is the amount riding on a clinical decision you do not control, which is the argument for reading the pricing model before the headline number.

Where every dollar goes at MEDVi

At a 10 mg maintenance dose the $399 you pay splits into $399 of medication and dispensing and nothing else recurring.

That single-figure structure is worth more than it looks. Membership stacking is the mechanism by which an advertised number becomes a materially larger invoice, and it is invisible in most published tables because they compare medication prices rather than totals.

What the figure does not include: laboratory work if the programme requires it, expedited shipping surcharges, and anything billed irregularly. Those are priced separately on the hidden-fee checklist rather than folded into a monthly number, because folding irregular charges into a recurring figure would be its own distortion.

How many programmes beat MEDVi on a first year

12 of the 15 other priced programmes come in below MEDVi over a first year; 2 come in above. The cheapest is NexLife at $2,580, a difference of $2,208.

Whether that gap is worth paying turns on what MEDVi provides that the cheaper route does not. Compare the disclosure rows rather than the price rows: pharmacy identity, prescriber licensure, cancellation terms and whether the quoted rate holds at renewal.

Bear in mind that 15 tracked programmes publish no price at all. They are not cheaper or dearer; they are unmeasurable, and their pages say so rather than carrying an estimate.

What flat pricing is worth at MEDVi, in dollars

At $399 flat, escalating from the starter dose to the ceiling costs nothing extra. The equivalent journey on the steepest dose-scaled programme we track adds $254 a month by the time you reach 15 mg.

The trade is that you pay the maintenance rate during the two titration months when you are receiving a quarter of the drug. At MEDVi that costs $798 for roughly 30 mg of active drug — a poor per-milligram figure, bought deliberately as insurance against a dose decision nobody has made yet.

Cost by maintenance dose and duration

A single annual figure assumes one maintenance dose, and nobody knows theirs at intake. This is what MEDVi costs across every plausible outcome over one, two and three years. The withdrawal evidence for this drug class shows substantial regain after stopping, so three years is a more honest planning horizon than twelve months.

How the price behaves as your dose climbs

MEDVi charges $399 at 2.5 mg and $399 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you are still paying in month ten. That predictability is worth more than most entry discounts, because nobody knows at intake where a prescriber will land them.

The corollary is that flat pricing is worst value at the bottom of the ladder and best at the top. In month one you pay a maintenance rate for an initiation dose. If you already know you will hold at 5 mg permanently — a legitimate clinical outcome when the response is adequate — a dose-scaled programme may beat this one.

Over three years at a 10 mg maintenance dose, holding here costs about $14,364 before any prepaid discount, and that figure does not move if your prescriber raises your dose.

What is bundled and what is billed separately

MEDVi charges no separate recurring platform fee, so the advertised figure and the figure on your statement are the same thing. Membership stacking is the mechanism by which a headline number becomes a larger invoice, and it is invisible in tables that compare medication prices rather than totals.

It also makes the programme easy to price honestly: one number, at a stated dose, with nothing arriving later that was not disclosed at the start.

Commitment, refunds and what is recoverable

The published prepaid rate is $249 a month on the multi-month plan, against $399 month-to-month at maintenance — a saving of $150 a month, $1,800 across a year.

It also converts a monthly decision into one that is effectively final. Compounded medication is generally not refundable once shipped, so a term entered during titration commits money against the most likely reason to stop: not tolerating the drug. Monthly until you have held a maintenance dose for a cycle, prepaid after.

Two questions before committing: does the discounted rate hold for the whole term or revert at renewal, and what happens if a clinician stops your prescription mid-term.

MEDVi against the programmes priced closest to it

Comparing against the whole market is noise. Comparing against the three routes nearest your price point is a decision, because those are the programmes a real shopper is weighing.

Pausing or restarting

Pausing costs more than it looks, and the cost is clinical before it is financial. Stop for a month and appetite returns before the metabolic adaptation to a lower weight does; stop for several and most prescribers restart low and re-titrate.

On this pricing, re-titration means two months back at $399 and $399 — the same as maintenance here, so the penalty is purely lost time and regained weight.

If cost is the reason for a pause, price the market before stopping. The cheapest tracked route, NexLife, runs about $2,580 a year against $4,788 here. Switching is almost always better than interrupting, because the interruption is what undoes the result.

Switching to or from this programme

Moving means a new clinical review and two risks worth planning around: a supply gap while an intake is processed, and a new prescriber restarting titration rather than continuing your dose. Do not cancel anything until the new programme has shipped.

Ask for dose continuity in writing before you move. Most programmes continue an established patient after review; the ones that will not are exactly the ones that will not say so until you have already cancelled.

Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Vial concentrations are not standardised between compounders, so carrying dosing instructions from an old vial to a new one is a genuine hazard rather than a theoretical one.

Eight questions to ask before you enrol

1. What will I pay in total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state, and can I have their name?
4. What is the vial concentration, and what is the beyond-use date?
5. Does the quoted rate hold at renewal, or does it revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel before the next cycle, and what is refundable?
8. Will you continue me at my current dose if I transfer in, or restart titration?

None requires clinical training to evaluate and all are answerable in writing. A programme that answers all eight is behaving well. A programme that deflects the pharmacy question has told you what you needed to know, and no headline number compensates for it.

What this programme discloses before you pay

Pharmacy: not named. Visit model: async. Laboratory requirement: not required. Coaching: none published. Cancellation: 12-month plan for lowest rate.

Naming the dispensing pharmacy is the most useful disclosure any programme can make, because it is the one fact that lets you check a public state board register before injecting something weekly. Fewer than a fifth of the programmes we price publish it, and those that do are not systematically more expensive.

None of this measures clinical quality. A programme can name six pharmacies and ship late; another can name none and employ careful clinicians. What disclosure measures is how much you can verify before handing over money and a medical history.

What would change our record

A published price at a dose tier currently blank. A named dispensing pharmacy with a checkable state licence. A change to the pricing model in either direction. Or a correction from a reader or from the programme itself with a source we can check.

All four are logged with the date they changed, and the underlying record sits in the open dataset rather than locked inside a page. We do not accept payment to change any of it, and no programme has editorial input here.

Using this programme well if you do enrol

Fix a weekly injection day and keep it. Record the dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if there is an introductory rate.

And re-price the market annually at your actual maintenance dose. No programme tells its existing patients when a competitor drops below it, and the cheapest tracked route currently sits at $215 a month all-in.

Where MEDVi sits in that spread

At $399 a month all-in at a 10 mg maintenance dose, MEDVi is about 86% above the cheapest tracked route, NexLife, at $215. Over a first year that is $4,788 against $2,580.

Whether the difference is worth paying is a question about what this programme provides that the cheaper one does not, and about how much of that you will use. It is not a question about the medicine, which is the same molecule from the same category of licensed pharmacy.

How the price behaves as your dose climbs

MEDVi charges $399 at 2.5 mg and $399 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you pay in month ten. That predictability is worth more than most entry discounts, and it is the single clearest thing this programme does well.

The corollary is that flat pricing is worst value at the bottom of the ladder. In month one you are paying a maintenance rate for an initiation dose. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled competitor may well beat this one.

What a longer horizon costs here

Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.

Commitment, refunds and what is at risk

The published prepaid rate is $249 a month on the multi-month plan, against $399 month to month — a saving of $150 a month. Compounded medication is generally not refundable once it ships, so treat the commitment as final. The sequencing that protects you is monthly billing until you have tolerated a maintenance dose for a cycle, prepaid after.

Cancellation: 12-month plan for lowest rate. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.

What this programme does not publish

MEDVi publishes everything our disclosure criteria measure, which is unusual. That is a statement about transparency, not about clinical quality or shipping reliability.

Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.

Seven questions before you enrol

1. What is the total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state?
4. What is the vial concentration and the beyond-use date?
5. Does the quoted rate hold at renewal, or revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel, and what is refundable before shipment?

None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.

Using it well if you do enrol

Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.

What MEDVi costs at each maintenance dose, over three years

Nobody knows their maintenance dose at intake, so a single annual figure is a guess about a decision a prescriber has not made. This is every plausible outcome for MEDVi, priced.

The spread between the cheapest and dearest outcome here is $0 a year. That is the amount riding on a clinical decision you do not control, which is the argument for reading the pricing model before the headline number.

Where every dollar goes at MEDVi

At a 10 mg maintenance dose the $399 you pay splits into $399 of medication and dispensing and nothing else recurring.

That single-figure structure is worth more than it looks. Membership stacking is the mechanism by which an advertised number becomes a materially larger invoice, and it is invisible in most published tables because they compare medication prices rather than totals.

What the figure does not include: laboratory work if the programme requires it, expedited shipping surcharges, and anything billed irregularly. Those are priced separately on the hidden-fee checklist rather than folded into a monthly number, because folding irregular charges into a recurring figure would be its own distortion.

How many programmes beat MEDVi on a first year

12 of the 15 other priced programmes come in below MEDVi over a first year; 2 come in above. The cheapest is NexLife at $2,580, a difference of $2,208.

Whether that gap is worth paying turns on what MEDVi provides that the cheaper route does not. Compare the disclosure rows rather than the price rows: pharmacy identity, prescriber licensure, cancellation terms and whether the quoted rate holds at renewal.

Bear in mind that 15 tracked programmes publish no price at all. They are not cheaper or dearer; they are unmeasurable, and their pages say so rather than carrying an estimate.

What flat pricing is worth at MEDVi, in dollars

At $399 flat, escalating from the starter dose to the ceiling costs nothing extra. The equivalent journey on the steepest dose-scaled programme we track adds $254 a month by the time you reach 15 mg.

The trade is that you pay the maintenance rate during the two titration months when you are receiving a quarter of the drug. At MEDVi that costs $798 for roughly 30 mg of active drug — a poor per-milligram figure, bought deliberately as insurance against a dose decision nobody has made yet.

Where MEDVi lands on price

MEDVi sits 13 of 16 on first-year all-in cost, at $399 a month all-in at a 10 mg maintenance dose and about $4,788 across a first year including titration. That is $2,208 more than NexLife across a first year, a 86% premium, and above the $349 median monthly figure.

12 programmes we track come in cheaper on a first-year basis. That is worth stating plainly on a page about MEDVi: if price is the only criterion, this is not the answer, and the cheaper options are listed at the price index.

What flat pricing is worth at MEDVi

MEDVi holds $399 at every strength from 2.5 mg to 15 mg. The figure you pay in month one is the figure you pay at maintenance, so titration carries no price consequence here.

Against a dose-scaled programme, that is worth most to someone who ends up high on the ladder and least to someone who settles at 5 mg. Since nobody knows at signup where they will settle, flat pricing is better understood as insurance against an unknown than as a lower price. At $399 it is above the $349 median, so the insurance is not free at this programme.

What MEDVi does not charge

There is no membership, platform or subscription fee at MEDVi. The $399 covers medication and mandatory recurring costs, which makes the advertised figure and the billed figure the same number.

That is less common than it should be: of the 16 priced programmes here, 5 charge a separate recurring fee. Where they do, the advertised medication price understates the bill.

The prepaid rate at MEDVi

Committing to a prepaid plan brings MEDVi to $249 a month, $150 below the month-to-month rate and a 38% reduction.

The saving is real and so is the exposure. Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months, which is exactly the window a prepaid term covers. Committing during titration puts $2,988 against the period you are least certain you will continue. Committing after reaching a maintenance dose you tolerate is a different and much better bet.

Semaglutide at MEDVi, for comparison

MEDVi also dispenses compounded semaglutide at $134 a month all-in, $265 below its tirzepatide price — a 66% difference for the other molecule at the same programme, the same clinicians and the same fulfilment.

That gap is close to the market norm and it is structural. Semaglutide is a shorter peptide with a longer manufacturing history and more compounding pharmacies equipped to produce it; tirzepatide is harder to synthesise and its active ingredient sells at a premium. Neither figure is subsidising the other.

Whether the tirzepatide premium is worth $3,180 across a year is a clinical question, not a pricing one. SURMOUNT-5 reported greater mean weight reduction on tirzepatide over 72 weeks, which is the strongest direct evidence available; semaglutide carries the larger cardiovascular outcomes base. If cost is the binding constraint, the cheaper molecule you can sustain for three years is a better bet than the dearer one you stop after eight months, because weight returns when either drug stops.

Who fills a MEDVi prescription

MEDVi does not name the dispensing pharmacy before purchase. That is common and it is not by itself a red flag, but it removes the only verification a patient can perform independently: checking the licence on a state board register.

If you enrol, ask in writing which pharmacy will fill the prescription, whether it is a 503A compounder or a 503B outsourcing facility, and request the certificate of analysis for your lot. A programme unwilling to answer those three questions in writing has told you something.

Where the evidence stops

The trial evidence for tirzepatide concerns the approved product at studied doses. It does not extend to compounded preparations, to microdosing schedules marketed as a cheaper entry point, or to combination vials with added vitamins. Those may be reasonable in practice, but the evidence base does not follow them.

Anyone citing trial outcomes to sell a compounded preparation is borrowing credibility from a product they are not dispensing. The honest framing is that the molecule has strong evidence behind it and the specific preparation in the vial has the pharmacy's assurance behind it.

What the dose ladder means for your bill

The approved ladder runs 2.5, 5, 7.5, 10, 12.5 and 15 mg weekly. Clinical trials studied 5, 10 and 15 mg as maintenance arms; the intermediate steps exist for titration rather than as targets. Where a person settles is a clinical decision driven by response and tolerability, not a preference.

That matters commercially because a dose-scaled programme is quoting you a price for a decision your prescriber has not made yet. If you settle at 15 mg on a programme that reprices at every step, you will pay materially more than the figure that attracted you. If you settle at 5 mg, you may pay less than a flat programme would charge.

Flat pricing is therefore worst value at the bottom of the ladder and best at the top. It is less a lower price than insurance against an outcome nobody can predict at signup. The cheapest flat option we verify is NexLife at $215 a month all-in.

Compounded is not a generic, and the difference is technical

A generic medicine has demonstrated bioequivalence to a reference product and been approved on that basis. A compounded preparation has done neither. It contains the same active molecule, but the formulation, concentration, excipients, container and beyond-use dating are decisions made by the compounding pharmacy rather than specifications reviewed by a regulator.

Practically, that means two vials of compounded tirzepatide from different pharmacies are not necessarily interchangeable. Concentration varies between operations, which is why dosing instructions are given in units or millilitres rather than by the pen click a Zepbound user would recognise, and why switching programmes mid-course requires confirming the new concentration rather than assuming it.

None of that makes compounding illegitimate. It does move a layer of quality assurance from a federal review process onto a pharmacy you can, and should, check.